- Home
- CLPT vs GALT Comparison
CLPT vs GALT Comparison
Compare CLPT & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPT | GALT |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 467.9M | 397.3M |
| IPO Year | 2009 | 2008 |
Fundamental Metrics
Financial Performance| Metric | CLPT | GALT |
|---|---|---|
| Price | $9.11 | $3.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $23.50 | N/A |
| AVG Volume (30 Days) | ★ 649.3K | 190.7K |
| Earning Date | 10-28-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,971,000.00 | N/A |
| Revenue This Year | $32.54 | N/A |
| Revenue Next Year | $15.41 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 17.78 | N/A |
| 52 Week Low | $8.27 | $2.03 |
| 52 Week High | $27.27 | $7.13 |
Technical Indicators
Market Signals| Indicator | CLPT | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 31.63 | 32.30 |
| Support Level | $8.61 | $2.71 |
| Resistance Level | $15.30 | $3.30 |
| Average True Range (ATR) | 0.48 | 0.23 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 5.20 | 1.73 |
Price Performance
Historical ComparisonAbout CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.